Skip to main content
Top
Published in: Molecular Neurodegeneration 1/2010

Open Access 01-12-2010 | Review

Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease

Authors: Lonnie Schneider, Jianhua Zhang

Published in: Molecular Neurodegeneration | Issue 1/2010

Login to get access

Abstract

The pathological changes occurring in Parkinson's and several other neurodegenerative diseases are complex and poorly understood, but all clearly involve protein aggregation. Also frequently appearing in neurodegeneration is mitochondrial dysfunction which may precede, coincide or follow protein aggregation. These observations led to the concept that protein aggregation and mitochondrial dysfunction either arise from the same etiological factors or are interactive. Understanding the mechanisms and regulation of processes that lead to protein aggregation or mitochondrial dysfunction may therefore contribute to the design of better therapeutics. Clearance of protein aggregates and dysfunctional organelles is dependent on macroautophagy which is the process through which aged or damaged proteins and organelles are first degraded by the lysosome and then recycled. The macroautophagy-lysosomal pathway is essential for maintaining protein and energy homeostasis. Not surprisingly, failure of the lysosomal system has been implicated in diseases that have features of protein aggregation and mitochondrial dysfunction. This review summarizes 3 major topics: 1) the current understanding of Parkinson's disease pathogenesis in terms of accumulation of damaged proteins and reduction of cellular bioenergetics; 2) evolving insights into lysosomal function and biogenesis and the accumulating evidence that lysosomal dysfunction may cause or exacerbate Parkinsonian pathology and finally 3) the possibility that enhancing lysosomal function may provide a disease modifying therapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference de DC: The lysosome turns fifty. Nat Cell Biol. 2005, 7: 847-849. 10.1038/ncb0905-847. de DC: The lysosome turns fifty. Nat Cell Biol. 2005, 7: 847-849. 10.1038/ncb0905-847.
2.
go back to reference Fuertes G, Martin de Llano JJ, Villarroya A, Rivett AJ, Knecht E: Changes in the proteolytic activities of proteasomes and lysosomes in human fibroblasts produced by serum withdrawal, amino-acid deprivation and confluent conditions. Biochem J. 2003, 375: 75-86. 10.1042/BJ20030282.PubMedPubMedCentral Fuertes G, Martin de Llano JJ, Villarroya A, Rivett AJ, Knecht E: Changes in the proteolytic activities of proteasomes and lysosomes in human fibroblasts produced by serum withdrawal, amino-acid deprivation and confluent conditions. Biochem J. 2003, 375: 75-86. 10.1042/BJ20030282.PubMedPubMedCentral
3.
go back to reference Cuervo AM, Dice JF: Lysosomes, a meeting point of proteins, chaperones, and proteases. J Mol Med. 1998, 76: 6-12. 10.1007/s109-1998-8099-y.PubMed Cuervo AM, Dice JF: Lysosomes, a meeting point of proteins, chaperones, and proteases. J Mol Med. 1998, 76: 6-12. 10.1007/s109-1998-8099-y.PubMed
4.
go back to reference Mortimore GE, Poso AR, Lardeux BR: Mechanism and regulation of protein degradation in liver. Diabetes Metab Rev. 1989, 5: 49-70. 10.1002/dmr.5610050105.PubMed Mortimore GE, Poso AR, Lardeux BR: Mechanism and regulation of protein degradation in liver. Diabetes Metab Rev. 1989, 5: 49-70. 10.1002/dmr.5610050105.PubMed
5.
go back to reference Nixon RA, Yang DS, Lee JH: Neurodegenerative lysosomal disorders: a continuum from development to late age. Autophagy. 2008, 4: 590-599.PubMed Nixon RA, Yang DS, Lee JH: Neurodegenerative lysosomal disorders: a continuum from development to late age. Autophagy. 2008, 4: 590-599.PubMed
6.
go back to reference Cuervo AM, Dice JF: When lysosomes get old. Exp Gerontol. 2000, 35: 119-131. 10.1016/S0531-5565(00)00075-9.PubMed Cuervo AM, Dice JF: When lysosomes get old. Exp Gerontol. 2000, 35: 119-131. 10.1016/S0531-5565(00)00075-9.PubMed
7.
go back to reference Lee VM, Trojanowski JQ: Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron. 2006, 52: 33-38. 10.1016/j.neuron.2006.09.026.PubMed Lee VM, Trojanowski JQ: Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron. 2006, 52: 33-38. 10.1016/j.neuron.2006.09.026.PubMed
8.
go back to reference Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al: alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003, 302: 841-10.1126/science.1090278.PubMed Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al: alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003, 302: 841-10.1126/science.1090278.PubMed
9.
go back to reference Giasson BI, Jakes R, Goedert M, Duda JE, Leight S, Trojanowski JQ, et al: A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J Neurosci Res. 2000, 59: 528-533. 10.1002/(SICI)1097-4547(20000215)59:4<528::AID-JNR8>3.0.CO;2-0.PubMed Giasson BI, Jakes R, Goedert M, Duda JE, Leight S, Trojanowski JQ, et al: A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J Neurosci Res. 2000, 59: 528-533. 10.1002/(SICI)1097-4547(20000215)59:4<528::AID-JNR8>3.0.CO;2-0.PubMed
10.
go back to reference Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M: Alpha-synuclein in Lewy bodies. Nature. 1997, 388: 839-840. 10.1038/42166.PubMed Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M: Alpha-synuclein in Lewy bodies. Nature. 1997, 388: 839-840. 10.1038/42166.PubMed
11.
go back to reference Klivenyi P, Siwek D, Gardian G, Yang L, Starkov A, Cleren C, et al: Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol Dis. 2006, 21: 541-548. 10.1016/j.nbd.2005.08.018.PubMed Klivenyi P, Siwek D, Gardian G, Yang L, Starkov A, Cleren C, et al: Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol Dis. 2006, 21: 541-548. 10.1016/j.nbd.2005.08.018.PubMed
12.
go back to reference Drolet RE, Behrouz B, Lookingland KJ, Goudreau JL: Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. Neurotoxicology. 2004, 25: 761-769. 10.1016/j.neuro.2004.05.002.PubMed Drolet RE, Behrouz B, Lookingland KJ, Goudreau JL: Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. Neurotoxicology. 2004, 25: 761-769. 10.1016/j.neuro.2004.05.002.PubMed
13.
go back to reference Robertson DC, Schmidt O, Ninkina N, Jones PA, Sharkey J, Buchman VL: Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice. J Neurochem. 2004, 89: 1126-1136. 10.1111/j.1471-4159.2004.02378.x.PubMed Robertson DC, Schmidt O, Ninkina N, Jones PA, Sharkey J, Buchman VL: Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice. J Neurochem. 2004, 89: 1126-1136. 10.1111/j.1471-4159.2004.02378.x.PubMed
14.
go back to reference Dauer W, Kholodilov N, Vila M, Trillat AC, Goodchild R, Larsen KE, et al: Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci USA. 2002, 99: 14524-14529. 10.1073/pnas.172514599.PubMedPubMedCentral Dauer W, Kholodilov N, Vila M, Trillat AC, Goodchild R, Larsen KE, et al: Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci USA. 2002, 99: 14524-14529. 10.1073/pnas.172514599.PubMedPubMedCentral
15.
go back to reference Hayashita-Kinoh H, Yamada M, Yokota T, Mizuno Y, Mochizuki H: Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model. Biochem Biophys Res Commun. 2006, 341: 1088-1095. 10.1016/j.bbrc.2006.01.057.PubMed Hayashita-Kinoh H, Yamada M, Yokota T, Mizuno Y, Mochizuki H: Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model. Biochem Biophys Res Commun. 2006, 341: 1088-1095. 10.1016/j.bbrc.2006.01.057.PubMed
16.
go back to reference Thomas B, Beal MF: Parkinson's disease. Hum Mol Genet. 2007, 16 (Spec No 2): R183-R194. 10.1093/hmg/ddm159.PubMed Thomas B, Beal MF: Parkinson's disease. Hum Mol Genet. 2007, 16 (Spec No 2): R183-R194. 10.1093/hmg/ddm159.PubMed
17.
go back to reference Mihajlovic M, Lazaridis T: Membrane-bound structure and energetics of alpha-synuclein. Proteins. 2008, 70: 761-778. 10.1002/prot.21558.PubMed Mihajlovic M, Lazaridis T: Membrane-bound structure and energetics of alpha-synuclein. Proteins. 2008, 70: 761-778. 10.1002/prot.21558.PubMed
18.
go back to reference Jao CC, Hegde BG, Chen J, Haworth IS, Langen R: Structure of membrane-bound alpha-synuclein from site-directed spin labeling and computational refinement. Proc Natl Acad Sci USA. 2008, 105: 19666-19671. 10.1073/pnas.0807826105.PubMedPubMedCentral Jao CC, Hegde BG, Chen J, Haworth IS, Langen R: Structure of membrane-bound alpha-synuclein from site-directed spin labeling and computational refinement. Proc Natl Acad Sci USA. 2008, 105: 19666-19671. 10.1073/pnas.0807826105.PubMedPubMedCentral
19.
go back to reference Pandey AP, Haque F, Rochet JC, Hovis JS: Clustering of alpha-synuclein on supported lipid bilayers: role of anionic lipid, protein, and divalent ion concentration. Biophys J. 2009, 96: 540-551. 10.1016/j.bpj.2008.10.011.PubMedPubMedCentral Pandey AP, Haque F, Rochet JC, Hovis JS: Clustering of alpha-synuclein on supported lipid bilayers: role of anionic lipid, protein, and divalent ion concentration. Biophys J. 2009, 96: 540-551. 10.1016/j.bpj.2008.10.011.PubMedPubMedCentral
20.
go back to reference Volles MJ, Lansbury PT: Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. J Mol Biol. 2007, 366: 1510-1522. 10.1016/j.jmb.2006.12.044.PubMedPubMedCentral Volles MJ, Lansbury PT: Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. J Mol Biol. 2007, 366: 1510-1522. 10.1016/j.jmb.2006.12.044.PubMedPubMedCentral
21.
go back to reference Zakharov SD, Hulleman JD, Dutseva EA, Antonenko YN, Rochet JC, Cramer WA: Helical alpha-synuclein forms highly conductive ion channels. Biochemistry. 2007, 46: 14369-14379. 10.1021/bi701275p.PubMed Zakharov SD, Hulleman JD, Dutseva EA, Antonenko YN, Rochet JC, Cramer WA: Helical alpha-synuclein forms highly conductive ion channels. Biochemistry. 2007, 46: 14369-14379. 10.1021/bi701275p.PubMed
22.
go back to reference Kubo S, Nemani VM, Chalkley RJ, Anthony MD, Hattori N, Mizuno Y, et al: A combinatorial code for the interaction of alpha-synuclein with membranes. J Biol Chem. 2005, 280: 31664-31672. 10.1074/jbc.M504894200.PubMed Kubo S, Nemani VM, Chalkley RJ, Anthony MD, Hattori N, Mizuno Y, et al: A combinatorial code for the interaction of alpha-synuclein with membranes. J Biol Chem. 2005, 280: 31664-31672. 10.1074/jbc.M504894200.PubMed
23.
go back to reference Rochet JC, Outeiro TF, Conway KA, Ding TT, Volles MJ, Lashuel HA, et al: Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J Mol Neurosci. 2004, 23: 23-34. 10.1385/JMN:23:1-2:023.PubMed Rochet JC, Outeiro TF, Conway KA, Ding TT, Volles MJ, Lashuel HA, et al: Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J Mol Neurosci. 2004, 23: 23-34. 10.1385/JMN:23:1-2:023.PubMed
24.
go back to reference Zhu M, Li J, Fink AL: The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation. J Biol Chem. 2003, 278: 40186-40197. 10.1074/jbc.M305326200.PubMed Zhu M, Li J, Fink AL: The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation. J Biol Chem. 2003, 278: 40186-40197. 10.1074/jbc.M305326200.PubMed
25.
go back to reference Zhu M, Fink AL: Lipid binding inhibits alpha-synuclein fibril formation. J Biol Chem. 2003, 278: 16873-16877. 10.1074/jbc.M210136200.PubMed Zhu M, Fink AL: Lipid binding inhibits alpha-synuclein fibril formation. J Biol Chem. 2003, 278: 16873-16877. 10.1074/jbc.M210136200.PubMed
26.
go back to reference Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, et al: Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci. 2002, 22: 8797-8807.PubMed Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, et al: Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci. 2002, 22: 8797-8807.PubMed
27.
go back to reference Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, et al: Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 2000, 25: 239-252. 10.1016/S0896-6273(00)80886-7.PubMed Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, et al: Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 2000, 25: 239-252. 10.1016/S0896-6273(00)80886-7.PubMed
28.
go back to reference Sharon R, Bar-Joseph I, Mirick GE, Serhan CN, Selkoe DJ: Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. J Biol Chem. 2003, 278: 49874-49881. 10.1074/jbc.M309127200.PubMed Sharon R, Bar-Joseph I, Mirick GE, Serhan CN, Selkoe DJ: Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. J Biol Chem. 2003, 278: 49874-49881. 10.1074/jbc.M309127200.PubMed
29.
go back to reference Fortin DL, Nemani VM, Voglmaier SM, Anthony MD, Ryan TA, Edwards RH: Neural activity controls the synaptic accumulation of alpha-synuclein. J Neurosci. 2005, 25: 10913-10921. 10.1523/JNEUROSCI.2922-05.2005.PubMed Fortin DL, Nemani VM, Voglmaier SM, Anthony MD, Ryan TA, Edwards RH: Neural activity controls the synaptic accumulation of alpha-synuclein. J Neurosci. 2005, 25: 10913-10921. 10.1523/JNEUROSCI.2922-05.2005.PubMed
30.
go back to reference George JM, Jin H, Woods WS, Clayton DF: Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron. 1995, 15: 361-372. 10.1016/0896-6273(95)90040-3.PubMed George JM, Jin H, Woods WS, Clayton DF: Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron. 1995, 15: 361-372. 10.1016/0896-6273(95)90040-3.PubMed
31.
go back to reference Perlmutter JD, Braun AR, Sachs JN: Curvature dynamics of alpha-synuclein familial Parkinson disease mutants: molecular simulations of the micelle- and bilayer-bound forms. J Biol Chem. 2009, 284: 7177-7189. 10.1074/jbc.M808895200.PubMedPubMedCentral Perlmutter JD, Braun AR, Sachs JN: Curvature dynamics of alpha-synuclein familial Parkinson disease mutants: molecular simulations of the micelle- and bilayer-bound forms. J Biol Chem. 2009, 284: 7177-7189. 10.1074/jbc.M808895200.PubMedPubMedCentral
32.
go back to reference Martin LJ, Pan Y, Price AC, Sterling W, Copeland NG, Jenkins NA, et al: Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci. 2006, 26: 41-50. 10.1523/JNEUROSCI.4308-05.2006.PubMed Martin LJ, Pan Y, Price AC, Sterling W, Copeland NG, Jenkins NA, et al: Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci. 2006, 26: 41-50. 10.1523/JNEUROSCI.4308-05.2006.PubMed
33.
go back to reference Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM: Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 2002, 34: 521-533. 10.1016/S0896-6273(02)00682-7.PubMed Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM: Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 2002, 34: 521-533. 10.1016/S0896-6273(02)00682-7.PubMed
34.
go back to reference Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, et al: Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 2000, 287: 1265-1269. 10.1126/science.287.5456.1265.PubMed Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, et al: Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 2000, 287: 1265-1269. 10.1126/science.287.5456.1265.PubMed
35.
go back to reference Clough RL, Dermentzaki G, Stefanis L: Functional dissection of the alpha-synuclein promoter: transcriptional regulation by ZSCAN21 and ZNF219. J Neurochem. 2009, 110: 1479-1490. 10.1111/j.1471-4159.2009.06250.x.PubMed Clough RL, Dermentzaki G, Stefanis L: Functional dissection of the alpha-synuclein promoter: transcriptional regulation by ZSCAN21 and ZNF219. J Neurochem. 2009, 110: 1479-1490. 10.1111/j.1471-4159.2009.06250.x.PubMed
36.
go back to reference Clough RL, Stefanis L: A novel pathway for transcriptional regulation of alpha-synuclein. FASEB J. 2007, 21: 596-607. 10.1096/fj.06-7111com.PubMed Clough RL, Stefanis L: A novel pathway for transcriptional regulation of alpha-synuclein. FASEB J. 2007, 21: 596-607. 10.1096/fj.06-7111com.PubMed
37.
go back to reference Scherzer CR, Grass JA, Liao Z, Pepivani I, Zheng B, Eklund AC, et al: GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc Natl Acad Sci USA. 2008, 105: 10907-10912. 10.1073/pnas.0802437105.PubMedPubMedCentral Scherzer CR, Grass JA, Liao Z, Pepivani I, Zheng B, Eklund AC, et al: GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc Natl Acad Sci USA. 2008, 105: 10907-10912. 10.1073/pnas.0802437105.PubMedPubMedCentral
38.
go back to reference Nuber S, Petrasch-Parwez E, Winner B, Winkler J, von HS, Schmidt T, et al: Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. J Neurosci. 2008, 28: 2471-2484. 10.1523/JNEUROSCI.3040-07.2008.PubMed Nuber S, Petrasch-Parwez E, Winner B, Winkler J, von HS, Schmidt T, et al: Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. J Neurosci. 2008, 28: 2471-2484. 10.1523/JNEUROSCI.3040-07.2008.PubMed
39.
go back to reference Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, et al: Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron. 2005, 46: 857-868. 10.1016/j.neuron.2005.05.010.PubMed Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, et al: Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron. 2005, 46: 857-868. 10.1016/j.neuron.2005.05.010.PubMed
40.
go back to reference Cantuti-Castelvetri I, Klucken J, Ingelsson M, Ramasamy K, McLean PJ, Frosch MP, et al: Alpha-synuclein and chaperones in dementia with Lewy bodies. J Neuropathol Exp Neurol. 2005, 64: 1058-1066. 10.1097/01.jnen.0000190063.90440.69.PubMed Cantuti-Castelvetri I, Klucken J, Ingelsson M, Ramasamy K, McLean PJ, Frosch MP, et al: Alpha-synuclein and chaperones in dementia with Lewy bodies. J Neuropathol Exp Neurol. 2005, 64: 1058-1066. 10.1097/01.jnen.0000190063.90440.69.PubMed
41.
go back to reference Li W, Lesuisse C, Xu Y, Troncoso JC, Price DL, Lee MK: Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation. J Neurosci. 2004, 24: 7400-7409. 10.1523/JNEUROSCI.1370-04.2004.PubMed Li W, Lesuisse C, Xu Y, Troncoso JC, Price DL, Lee MK: Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation. J Neurosci. 2004, 24: 7400-7409. 10.1523/JNEUROSCI.1370-04.2004.PubMed
42.
go back to reference Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD: Mitochondrial complex I deficiency in Parkinson's disease. Lancet. 1989, 1: 1269-10.1016/S0140-6736(89)92366-0.PubMed Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD: Mitochondrial complex I deficiency in Parkinson's disease. Lancet. 1989, 1: 1269-10.1016/S0140-6736(89)92366-0.PubMed
43.
go back to reference Keeney PM, Xie J, Capaldi RA, Bennett JP: Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci. 2006, 26: 5256-5264. 10.1523/JNEUROSCI.0984-06.2006.PubMed Keeney PM, Xie J, Capaldi RA, Bennett JP: Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci. 2006, 26: 5256-5264. 10.1523/JNEUROSCI.0984-06.2006.PubMed
44.
go back to reference Parker WD, Parks JK, Swerdlow RH: Complex I deficiency in Parkinson's disease frontal cortex. Brain Res. 2008, 1189: 215-218. 10.1016/j.brainres.2007.10.061.PubMedPubMedCentral Parker WD, Parks JK, Swerdlow RH: Complex I deficiency in Parkinson's disease frontal cortex. Brain Res. 2008, 1189: 215-218. 10.1016/j.brainres.2007.10.061.PubMedPubMedCentral
45.
go back to reference Smigrodzki R, Parks J, Parker WD: High frequency of mitochondrial complex I mutations in Parkinson's disease and aging. Neurobiol Aging. 2004, 25: 1273-1281. 10.1016/j.neurobiolaging.2004.02.020.PubMed Smigrodzki R, Parks J, Parker WD: High frequency of mitochondrial complex I mutations in Parkinson's disease and aging. Neurobiol Aging. 2004, 25: 1273-1281. 10.1016/j.neurobiolaging.2004.02.020.PubMed
46.
go back to reference Arthur CR, Morton SL, Dunham LD, Keeney PM, Bennett JP: Parkinson's disease brain mitochondria have impaired respirasome assembly, age-related increases in distribution of oxidative damage to mtDNA and no differences in heteroplasmic mtDNA mutation abundance. Mol Neurodegener. 2009, 4: 37-10.1186/1750-1326-4-37.PubMedPubMedCentral Arthur CR, Morton SL, Dunham LD, Keeney PM, Bennett JP: Parkinson's disease brain mitochondria have impaired respirasome assembly, age-related increases in distribution of oxidative damage to mtDNA and no differences in heteroplasmic mtDNA mutation abundance. Mol Neurodegener. 2009, 4: 37-10.1186/1750-1326-4-37.PubMedPubMedCentral
47.
go back to reference Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, et al: High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet. 2006, 38: 515-517. 10.1038/ng1769.PubMed Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, et al: High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet. 2006, 38: 515-517. 10.1038/ng1769.PubMed
48.
go back to reference Simon DK, Lin MT, Zheng L, Liu GJ, Ahn CH, Kim LM, et al: Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease. Neurobiol Aging. 2004, 25: 71-81. 10.1016/S0197-4580(03)00037-X.PubMed Simon DK, Lin MT, Zheng L, Liu GJ, Ahn CH, Kim LM, et al: Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease. Neurobiol Aging. 2004, 25: 71-81. 10.1016/S0197-4580(03)00037-X.PubMed
49.
go back to reference Soong NW, Hinton DR, Cortopassi G, Arnheim N: Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain. Nat Genet. 1992, 2: 318-323. 10.1038/ng1292-318.PubMed Soong NW, Hinton DR, Cortopassi G, Arnheim N: Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain. Nat Genet. 1992, 2: 318-323. 10.1038/ng1292-318.PubMed
50.
go back to reference Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, Beal MF, Wallace DC: Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nat Genet. 1992, 2: 324-329. 10.1038/ng1292-324.PubMed Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, Beal MF, Wallace DC: Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nat Genet. 1992, 2: 324-329. 10.1038/ng1292-324.PubMed
51.
go back to reference Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, et al: Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science. 2005, 307: 1282-1288. 10.1126/science.1105681.PubMed Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, et al: Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science. 2005, 307: 1282-1288. 10.1126/science.1105681.PubMed
52.
go back to reference Li H, Li SH, Yu ZX, Shelbourne P, Li XJ: Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J Neurosci. 2001, 21: 8473-8481.PubMed Li H, Li SH, Yu ZX, Shelbourne P, Li XJ: Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J Neurosci. 2001, 21: 8473-8481.PubMed
53.
go back to reference Galvin JE, Uryu K, Lee VM, Trojanowski JQ: Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc Natl Acad Sci USA. 1999, 96: 13450-13455. 10.1073/pnas.96.23.13450.PubMedPubMedCentral Galvin JE, Uryu K, Lee VM, Trojanowski JQ: Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc Natl Acad Sci USA. 1999, 96: 13450-13455. 10.1073/pnas.96.23.13450.PubMedPubMedCentral
54.
go back to reference Braak H, Ghebremedhin E, Rub U, Bratzke H, Del TK: Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004, 318: 121-134. 10.1007/s00441-004-0956-9.PubMed Braak H, Ghebremedhin E, Rub U, Bratzke H, Del TK: Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004, 318: 121-134. 10.1007/s00441-004-0956-9.PubMed
55.
go back to reference Langston JW, Ballard P: Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. Can J Neurol Sci. 1984, 11: 160-165.PubMed Langston JW, Ballard P: Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. Can J Neurol Sci. 1984, 11: 160-165.PubMed
56.
go back to reference Langston JW, Langston EB, Irwin I: MPTP-induced parkinsonism in human and non-human primates--clinical and experimental aspects. Acta Neurol Scand Suppl. 1984, 100: 49-54.PubMed Langston JW, Langston EB, Irwin I: MPTP-induced parkinsonism in human and non-human primates--clinical and experimental aspects. Acta Neurol Scand Suppl. 1984, 100: 49-54.PubMed
57.
go back to reference Langston JW, Ballard PA: Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N Engl J Med. 1983, 309: 310-PubMed Langston JW, Ballard PA: Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N Engl J Med. 1983, 309: 310-PubMed
58.
go back to reference Langston JW, Ballard P, Tetrud JW, Irwin I: Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983, 219: 979-980. 10.1126/science.6823561.PubMed Langston JW, Ballard P, Tetrud JW, Irwin I: Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983, 219: 979-980. 10.1126/science.6823561.PubMed
59.
go back to reference Bove J, Prou D, Perier C, Przedborski S: Toxin-induced models of Parkinson's disease. NeuroRx. 2005, 2: 484-494. 10.1602/neurorx.2.3.484.PubMedPubMedCentral Bove J, Prou D, Perier C, Przedborski S: Toxin-induced models of Parkinson's disease. NeuroRx. 2005, 2: 484-494. 10.1602/neurorx.2.3.484.PubMedPubMedCentral
60.
go back to reference Langston JW, Irwin I, Langston EB, Forno LS: 1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci Lett. 1984, 48: 87-92. 10.1016/0304-3940(84)90293-3.PubMed Langston JW, Irwin I, Langston EB, Forno LS: 1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci Lett. 1984, 48: 87-92. 10.1016/0304-3940(84)90293-3.PubMed
61.
go back to reference Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT: Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci. 2000, 3: 1301-1306. 10.1038/81834.PubMed Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT: Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci. 2000, 3: 1301-1306. 10.1038/81834.PubMed
62.
go back to reference Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, et al: An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci. 2002, 22: 7006-7015.PubMed Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, et al: An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci. 2002, 22: 7006-7015.PubMed
63.
go back to reference Gao HM, Liu B, Hong JS: Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci. 2003, 23: 6181-6187.PubMed Gao HM, Liu B, Hong JS: Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci. 2003, 23: 6181-6187.PubMed
64.
go back to reference Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, et al: Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci. 2003, 23: 10756-10764.PubMed Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, et al: Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci. 2003, 23: 10756-10764.PubMed
65.
go back to reference Trimmer PA, Bennett JP: The cybrid model of sporadic Parkinson's disease. Exp Neurol. 2009, 218: 320-325. 10.1016/j.expneurol.2009.03.016.PubMedPubMedCentral Trimmer PA, Bennett JP: The cybrid model of sporadic Parkinson's disease. Exp Neurol. 2009, 218: 320-325. 10.1016/j.expneurol.2009.03.016.PubMedPubMedCentral
66.
go back to reference Trimmer PA, Borland MK, Keeney PM, Bennett JP, Parker WD: Parkinson's disease transgenic mitochondrial cybrids generate Lewy inclusion bodies. J Neurochem. 2004, 88: 800-812.PubMed Trimmer PA, Borland MK, Keeney PM, Bennett JP, Parker WD: Parkinson's disease transgenic mitochondrial cybrids generate Lewy inclusion bodies. J Neurochem. 2004, 88: 800-812.PubMed
67.
go back to reference Ekstrand MI, Terzioglu M, Galter D, Zhu S, Hofstetter C, Lindqvist E, et al: Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci USA. 2007, 104: 1325-1330. 10.1073/pnas.0605208103.PubMedPubMedCentral Ekstrand MI, Terzioglu M, Galter D, Zhu S, Hofstetter C, Lindqvist E, et al: Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci USA. 2007, 104: 1325-1330. 10.1073/pnas.0605208103.PubMedPubMedCentral
68.
go back to reference Schapira AH: Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 2008, 7: 97-109. 10.1016/S1474-4422(07)70327-7.PubMed Schapira AH: Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 2008, 7: 97-109. 10.1016/S1474-4422(07)70327-7.PubMed
69.
go back to reference Nakamura K, Nemani VM, Wallender EK, Kaehlcke K, Ott M, Edwards RH: Optical reporters for the conformation of alpha-synuclein reveal a specific interaction with mitochondria. J Neurosci. 2008, 28: 12305-12317. 10.1523/JNEUROSCI.3088-08.2008.PubMed Nakamura K, Nemani VM, Wallender EK, Kaehlcke K, Ott M, Edwards RH: Optical reporters for the conformation of alpha-synuclein reveal a specific interaction with mitochondria. J Neurosci. 2008, 28: 12305-12317. 10.1523/JNEUROSCI.3088-08.2008.PubMed
70.
go back to reference Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK: Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem. 2008, 283: 9089-9100. 10.1074/jbc.M710012200.PubMedPubMedCentral Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK: Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem. 2008, 283: 9089-9100. 10.1074/jbc.M710012200.PubMedPubMedCentral
71.
go back to reference Parihar MS, Parihar A, Fujita M, Hashimoto M, Ghafourifar P: Mitochondrial association of alpha-synuclein causes oxidative stress. Cell Mol Life Sci. 2008, 65: 1272-1284. 10.1007/s00018-008-7589-1.PubMed Parihar MS, Parihar A, Fujita M, Hashimoto M, Ghafourifar P: Mitochondrial association of alpha-synuclein causes oxidative stress. Cell Mol Life Sci. 2008, 65: 1272-1284. 10.1007/s00018-008-7589-1.PubMed
72.
go back to reference Song DD, Shults CW, Sisk A, Rockenstein E, Masliah E: Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp Neurol. 2004, 186: 158-172. 10.1016/S0014-4886(03)00342-X.PubMed Song DD, Shults CW, Sisk A, Rockenstein E, Masliah E: Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp Neurol. 2004, 186: 158-172. 10.1016/S0014-4886(03)00342-X.PubMed
73.
go back to reference Elkon H, Don J, Melamed E, Ziv I, Shirvan A, Offen D: Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome C oxidase. J Mol Neurosci. 2002, 18: 229-238. 10.1385/JMN:18:3:229.PubMed Elkon H, Don J, Melamed E, Ziv I, Shirvan A, Offen D: Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome C oxidase. J Mol Neurosci. 2002, 18: 229-238. 10.1385/JMN:18:3:229.PubMed
74.
go back to reference Vila M, Vukosavic S, Jackson-Lewis V, Neystat M, Jakowec M, Przedborski S: Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem. 2000, 74: 721-729. 10.1046/j.1471-4159.2000.740721.x.PubMed Vila M, Vukosavic S, Jackson-Lewis V, Neystat M, Jakowec M, Przedborski S: Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem. 2000, 74: 721-729. 10.1046/j.1471-4159.2000.740721.x.PubMed
75.
go back to reference Meredith GE, Totterdell S, Potashkin JA, Surmeier DJ: Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat Disord. 2008, 14 (Suppl 2): S112-S115. 10.1016/j.parkreldis.2008.04.012.PubMedPubMedCentral Meredith GE, Totterdell S, Potashkin JA, Surmeier DJ: Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat Disord. 2008, 14 (Suppl 2): S112-S115. 10.1016/j.parkreldis.2008.04.012.PubMedPubMedCentral
76.
go back to reference Meredith GE, Halliday GM, Totterdell S: A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation. Parkinsonism Relat Disord. 2004, 10: 191-202. 10.1016/j.parkreldis.2004.01.001.PubMed Meredith GE, Halliday GM, Totterdell S: A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation. Parkinsonism Relat Disord. 2004, 10: 191-202. 10.1016/j.parkreldis.2004.01.001.PubMed
77.
go back to reference Meredith GE, Totterdell S, Petroske E, Santa CK, Callison RC, Lau YS: Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res. 2002, 956: 156-165. 10.1016/S0006-8993(02)03514-X.PubMed Meredith GE, Totterdell S, Petroske E, Santa CK, Callison RC, Lau YS: Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res. 2002, 956: 156-165. 10.1016/S0006-8993(02)03514-X.PubMed
78.
go back to reference Jackson-Lewis V, Przedborski S: Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc. 2007, 2: 141-151. 10.1038/nprot.2006.342.PubMed Jackson-Lewis V, Przedborski S: Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc. 2007, 2: 141-151. 10.1038/nprot.2006.342.PubMed
79.
go back to reference Petroske E, Meredith GE, Callen S, Totterdell S, Lau YS: Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience. 2001, 106: 589-601. 10.1016/S0306-4522(01)00295-0.PubMed Petroske E, Meredith GE, Callen S, Totterdell S, Lau YS: Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience. 2001, 106: 589-601. 10.1016/S0306-4522(01)00295-0.PubMed
80.
go back to reference Fountaine TM, Wade-Martins R: RNA interference-mediated knockdown of alpha-synuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. J Neurosci Res. 2007, 85: 351-363. 10.1002/jnr.21125.PubMed Fountaine TM, Wade-Martins R: RNA interference-mediated knockdown of alpha-synuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. J Neurosci Res. 2007, 85: 351-363. 10.1002/jnr.21125.PubMed
81.
go back to reference Yu WH, Matsuoka Y, Sziraki I, Hashim A, LaFrancois J, Sershen H, et al: Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in transgenic mice expressing mutant A53T alpha-synuclein. Neurochem Res. 2008, 33: 902-911. 10.1007/s11064-007-9533-4.PubMed Yu WH, Matsuoka Y, Sziraki I, Hashim A, LaFrancois J, Sershen H, et al: Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in transgenic mice expressing mutant A53T alpha-synuclein. Neurochem Res. 2008, 33: 902-911. 10.1007/s11064-007-9533-4.PubMed
82.
go back to reference Nieto M, Gil-Bea FJ, Dalfo E, Cuadrado M, Cabodevilla F, Sanchez B, et al: Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice. Neurobiol Aging. 2006, 27: 848-856. 10.1016/j.neurobiolaging.2005.04.010.PubMed Nieto M, Gil-Bea FJ, Dalfo E, Cuadrado M, Cabodevilla F, Sanchez B, et al: Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice. Neurobiol Aging. 2006, 27: 848-856. 10.1016/j.neurobiolaging.2005.04.010.PubMed
83.
go back to reference Settembre C, Fraldi A, Rubinsztein DC, Ballabio A: Lysosomal storage diseases as disorders of autophagy. Autophagy. 2008, 4: 113-114.PubMed Settembre C, Fraldi A, Rubinsztein DC, Ballabio A: Lysosomal storage diseases as disorders of autophagy. Autophagy. 2008, 4: 113-114.PubMed
84.
go back to reference Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, et al: Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. J Neurosci. 2008, 28: 6926-6937. 10.1523/JNEUROSCI.0800-08.2008.PubMedPubMedCentral Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, et al: Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. J Neurosci. 2008, 28: 6926-6937. 10.1523/JNEUROSCI.0800-08.2008.PubMedPubMedCentral
85.
go back to reference Lubke T, Lobel P, Sleat DE: Proteomics of the lysosome. Biochim Biophys Acta. 2009, 1793: 625-635. 10.1016/j.bbamcr.2008.09.018.PubMedPubMedCentral Lubke T, Lobel P, Sleat DE: Proteomics of the lysosome. Biochim Biophys Acta. 2009, 1793: 625-635. 10.1016/j.bbamcr.2008.09.018.PubMedPubMedCentral
86.
go back to reference Wang F, Duan R, Chirgwin J, Safe SH: Transcriptional activation of cathepsin D gene expression by growth factors. J Mol Endocrinol. 2000, 24: 193-202. 10.1677/jme.0.0240193.PubMed Wang F, Duan R, Chirgwin J, Safe SH: Transcriptional activation of cathepsin D gene expression by growth factors. J Mol Endocrinol. 2000, 24: 193-202. 10.1677/jme.0.0240193.PubMed
87.
go back to reference Sardiello M, Palmieri M, di RA, Medina DL, Valenza M, Gennarino VA, et al: A gene network regulating lysosomal biogenesis and function. Science. 2009, 325: 473-477.PubMed Sardiello M, Palmieri M, di RA, Medina DL, Valenza M, Gennarino VA, et al: A gene network regulating lysosomal biogenesis and function. Science. 2009, 325: 473-477.PubMed
88.
go back to reference Erickson AH, Conner GE, Blobel G: Biosynthesis of a lysosomal enzyme. Partial structure of two transient and functionally distinct NH2-terminal sequences in cathepsin D. J Biol Chem. 1981, 256: 11224-11231.PubMed Erickson AH, Conner GE, Blobel G: Biosynthesis of a lysosomal enzyme. Partial structure of two transient and functionally distinct NH2-terminal sequences in cathepsin D. J Biol Chem. 1981, 256: 11224-11231.PubMed
89.
go back to reference Erickson AH, Blobel G: Early events in the biosynthesis of the lysosomal enzyme cathepsin D. J Biol Chem. 1979, 254: 11771-11774.PubMed Erickson AH, Blobel G: Early events in the biosynthesis of the lysosomal enzyme cathepsin D. J Biol Chem. 1979, 254: 11771-11774.PubMed
90.
go back to reference Qian Y, Lee I, Lee WS, Qian M, Kudo M, Canfield WM, et al: Functions of the alpha, beta and gamma subunits of UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase. J Biol Chem. 2009, 285: 3360-3370. 10.1074/jbc.M109.068650.PubMedPubMedCentral Qian Y, Lee I, Lee WS, Qian M, Kudo M, Canfield WM, et al: Functions of the alpha, beta and gamma subunits of UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase. J Biol Chem. 2009, 285: 3360-3370. 10.1074/jbc.M109.068650.PubMedPubMedCentral
91.
go back to reference Kudo M, Brem MS, Canfield WM: Mucolipidosis II (I-cell disease) and mucolipidosis IIIA (classical pseudo-hurler polydystrophy) are caused by mutations in the GlcNAc-phosphotransferase alpha/beta -subunits precursor gene. Am J Hum Genet. 2006, 78: 451-463. 10.1086/500849.PubMedPubMedCentral Kudo M, Brem MS, Canfield WM: Mucolipidosis II (I-cell disease) and mucolipidosis IIIA (classical pseudo-hurler polydystrophy) are caused by mutations in the GlcNAc-phosphotransferase alpha/beta -subunits precursor gene. Am J Hum Genet. 2006, 78: 451-463. 10.1086/500849.PubMedPubMedCentral
92.
go back to reference Kudo M, Bao M, D'Souza A, Ying F, Pan H, Roe BA, et al: The alpha- and beta-subunits of the human UDP-N-acetylglucosamine:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase [corrected] are encoded by a single cDNA. J Biol Chem. 2005, 280: 36141-36149. 10.1074/jbc.M509008200.PubMed Kudo M, Bao M, D'Souza A, Ying F, Pan H, Roe BA, et al: The alpha- and beta-subunits of the human UDP-N-acetylglucosamine:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase [corrected] are encoded by a single cDNA. J Biol Chem. 2005, 280: 36141-36149. 10.1074/jbc.M509008200.PubMed
93.
go back to reference Braulke T, Bonifacino JS: Sorting of lysosomal proteins. Biochim Biophys Acta. 2009, 1793: 605-614. 10.1016/j.bbamcr.2008.10.016.PubMed Braulke T, Bonifacino JS: Sorting of lysosomal proteins. Biochim Biophys Acta. 2009, 1793: 605-614. 10.1016/j.bbamcr.2008.10.016.PubMed
94.
go back to reference Reczek D, Schwake M, Schroder J, Hughes H, Blanz J, Jin X, et al: LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell. 2007, 131: 770-783. 10.1016/j.cell.2007.10.018.PubMed Reczek D, Schwake M, Schroder J, Hughes H, Blanz J, Jin X, et al: LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell. 2007, 131: 770-783. 10.1016/j.cell.2007.10.018.PubMed
95.
go back to reference Lefrancois S, Zeng J, Hassan AJ, Canuel M, Morales CR: The lysosomal trafficking of sphingolipid activator proteins (SAPs) is mediated by sortilin. EMBO J. 2003, 22: 6430-6437. 10.1093/emboj/cdg629.PubMedPubMedCentral Lefrancois S, Zeng J, Hassan AJ, Canuel M, Morales CR: The lysosomal trafficking of sphingolipid activator proteins (SAPs) is mediated by sortilin. EMBO J. 2003, 22: 6430-6437. 10.1093/emboj/cdg629.PubMedPubMedCentral
96.
go back to reference Canuel M, Korkidakis A, Konnyu K, Morales CR: Sortilin mediates the lysosomal targeting of cathepsins D and H. Biochem Biophys Res Commun. 2008, 373: 292-297. 10.1016/j.bbrc.2008.06.021.PubMed Canuel M, Korkidakis A, Konnyu K, Morales CR: Sortilin mediates the lysosomal targeting of cathepsins D and H. Biochem Biophys Res Commun. 2008, 373: 292-297. 10.1016/j.bbrc.2008.06.021.PubMed
97.
go back to reference Canuel M, Libin Y, Morales CR: The interactomics of sortilin: an ancient lysosomal receptor evolving new functions. Histol Histopathol. 2009, 24: 481-492.PubMed Canuel M, Libin Y, Morales CR: The interactomics of sortilin: an ancient lysosomal receptor evolving new functions. Histol Histopathol. 2009, 24: 481-492.PubMed
98.
go back to reference Zeng J, Racicott J, Morales CR: The inactivation of the sortilin gene leads to a partial disruption of prosaposin trafficking to the lysosomes. Exp Cell Res. 2009, 315: 3112-3124. 10.1016/j.yexcr.2009.08.016.PubMed Zeng J, Racicott J, Morales CR: The inactivation of the sortilin gene leads to a partial disruption of prosaposin trafficking to the lysosomes. Exp Cell Res. 2009, 315: 3112-3124. 10.1016/j.yexcr.2009.08.016.PubMed
99.
go back to reference Blanz J, Groth J, Zachos C, Wehling C, Saftig P, Schwake M: Disease-causing mutations within the lysosomal integral membrane protein type 2 (LIMP-2) reveal the nature of binding to its ligand {beta}-glucocerebrosidase. Hum Mol Genet. 2010, 19: 563-72. 10.1093/hmg/ddp523.PubMed Blanz J, Groth J, Zachos C, Wehling C, Saftig P, Schwake M: Disease-causing mutations within the lysosomal integral membrane protein type 2 (LIMP-2) reveal the nature of binding to its ligand {beta}-glucocerebrosidase. Hum Mol Genet. 2010, 19: 563-72. 10.1093/hmg/ddp523.PubMed
100.
go back to reference Griffiths GM: Gaucher disease: forging a new path to the lysosome. Cell. 2007, 131: 647-649. 10.1016/j.cell.2007.10.043.PubMed Griffiths GM: Gaucher disease: forging a new path to the lysosome. Cell. 2007, 131: 647-649. 10.1016/j.cell.2007.10.043.PubMed
101.
go back to reference Berkovic SF, Dibbens LM, Oshlack A, Silver JD, Katerelos M, Vears DF, et al: Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis. Am J Hum Genet. 2008, 82: 673-684. 10.1016/j.ajhg.2007.12.019.PubMedPubMedCentral Berkovic SF, Dibbens LM, Oshlack A, Silver JD, Katerelos M, Vears DF, et al: Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis. Am J Hum Genet. 2008, 82: 673-684. 10.1016/j.ajhg.2007.12.019.PubMedPubMedCentral
102.
go back to reference Grear KE, Ling IF, Simpson JF, Furman JL, Simmons CR, Peterson SL, et al: Expression of SORL1 and a novel SORL1 splice variant in normal and Alzheimers disease brain. Mol Neurodegener. 2009, 4: 46-10.1186/1750-1326-4-46.PubMedPubMedCentral Grear KE, Ling IF, Simpson JF, Furman JL, Simmons CR, Peterson SL, et al: Expression of SORL1 and a novel SORL1 splice variant in normal and Alzheimers disease brain. Mol Neurodegener. 2009, 4: 46-10.1186/1750-1326-4-46.PubMedPubMedCentral
103.
go back to reference Minarowska A, Karwowska A, Gacko M: Quantitative determination and localization of cathepsin D and its inhibitors. Folia Histochem Cytobiol. 2009, 47: 153-177. 10.2478/v10042-009-0073-4.PubMed Minarowska A, Karwowska A, Gacko M: Quantitative determination and localization of cathepsin D and its inhibitors. Folia Histochem Cytobiol. 2009, 47: 153-177. 10.2478/v10042-009-0073-4.PubMed
104.
go back to reference Turk V, Stoka V, Turk D: Cystatins: biochemical and structural properties, and medical relevance. Front Biosci. 2008, 13: 5406-5420. 10.2741/3089.PubMed Turk V, Stoka V, Turk D: Cystatins: biochemical and structural properties, and medical relevance. Front Biosci. 2008, 13: 5406-5420. 10.2741/3089.PubMed
105.
go back to reference Gacko M, Minarowska A, Karwowska A, Minarowski L: Cathepsin D inhibitors. Folia Histochem Cytobiol. 2007, 45: 291-313.PubMed Gacko M, Minarowska A, Karwowska A, Minarowski L: Cathepsin D inhibitors. Folia Histochem Cytobiol. 2007, 45: 291-313.PubMed
106.
go back to reference Fischer EP, Holzer H: Interaction of proteinases and their inhibitors from yeast. Activation of carboxypeptidase Y. Biochim Biophys Acta. 1980, 615: 187-198.PubMed Fischer EP, Holzer H: Interaction of proteinases and their inhibitors from yeast. Activation of carboxypeptidase Y. Biochim Biophys Acta. 1980, 615: 187-198.PubMed
107.
go back to reference Heinrich M, Wickel M, Winoto-Morbach S, Schneider-Brachert W, Weber T, Brunner J, et al: Ceramide as an activator lipid of cathepsin D. Adv Exp Med Biol. 2000, 477: 305-315. full_text.PubMed Heinrich M, Wickel M, Winoto-Morbach S, Schneider-Brachert W, Weber T, Brunner J, et al: Ceramide as an activator lipid of cathepsin D. Adv Exp Med Biol. 2000, 477: 305-315. full_text.PubMed
108.
go back to reference Noda T, Fujita N, Yoshimori T: The late stages of autophagy: how does the end begin?. Cell Death Differ. 2009, 16: 984-990. 10.1038/cdd.2009.54.PubMed Noda T, Fujita N, Yoshimori T: The late stages of autophagy: how does the end begin?. Cell Death Differ. 2009, 16: 984-990. 10.1038/cdd.2009.54.PubMed
109.
go back to reference Kimura S, Noda T, Yoshimori T: Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy. 2007, 3: 452-460.PubMed Kimura S, Noda T, Yoshimori T: Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy. 2007, 3: 452-460.PubMed
110.
go back to reference Lucocq J, Walker D: Evidence for fusion between multilamellar endosomes and autophagosomes in HeLa cells. Eur J Cell Biol. 1997, 72: 307-313.PubMed Lucocq J, Walker D: Evidence for fusion between multilamellar endosomes and autophagosomes in HeLa cells. Eur J Cell Biol. 1997, 72: 307-313.PubMed
111.
go back to reference Kalatzis V, Nevo N, Cherqui S, Gasnier B, Antignac C: Molecular pathogenesis of cystinosis: effect of CTNS mutations on the transport activity and subcellular localization of cystinosin. Hum Mol Genet. 2004, 13: 1361-1371. 10.1093/hmg/ddh152.PubMed Kalatzis V, Nevo N, Cherqui S, Gasnier B, Antignac C: Molecular pathogenesis of cystinosis: effect of CTNS mutations on the transport activity and subcellular localization of cystinosin. Hum Mol Genet. 2004, 13: 1361-1371. 10.1093/hmg/ddh152.PubMed
112.
go back to reference Kalatzis V, Cherqui S, Antignac C, Gasnier B: Cystinosin, the protein defective in cystinosis, is a H(+)-driven lysosomal cystine transporter. EMBO J. 2001, 20: 5940-5949. 10.1093/emboj/20.21.5940.PubMedPubMedCentral Kalatzis V, Cherqui S, Antignac C, Gasnier B: Cystinosin, the protein defective in cystinosis, is a H(+)-driven lysosomal cystine transporter. EMBO J. 2001, 20: 5940-5949. 10.1093/emboj/20.21.5940.PubMedPubMedCentral
113.
go back to reference Sagne C, Agulhon C, Ravassard P, Darmon M, Hamon M, El MS, et al: Identification and characterization of a lysosomal transporter for small neutral amino acids. Proc Natl Acad Sci USA. 2001, 98: 7206-7211. 10.1073/pnas.121183498.PubMedPubMedCentral Sagne C, Agulhon C, Ravassard P, Darmon M, Hamon M, El MS, et al: Identification and characterization of a lysosomal transporter for small neutral amino acids. Proc Natl Acad Sci USA. 2001, 98: 7206-7211. 10.1073/pnas.121183498.PubMedPubMedCentral
114.
go back to reference Saftig P, Klumperman J: Lysosomal biogenesis and lysosomal membrane proteins: trafficking meets function. Nature Reviews. 2009, 10: 623-635.PubMed Saftig P, Klumperman J: Lysosomal biogenesis and lysosomal membrane proteins: trafficking meets function. Nature Reviews. 2009, 10: 623-635.PubMed
115.
go back to reference Ruivo R, Anne C, Sagne C, Gasnier B: Molecular and cellular basis of lysosomal transmembrane protein dysfunction. Biochim Biophys Acta. 2009, 1793: 636-649. 10.1016/j.bbamcr.2008.12.008.PubMed Ruivo R, Anne C, Sagne C, Gasnier B: Molecular and cellular basis of lysosomal transmembrane protein dysfunction. Biochim Biophys Acta. 2009, 1793: 636-649. 10.1016/j.bbamcr.2008.12.008.PubMed
116.
go back to reference Ballabio A, Gieselmann V: Lysosomal disorders: from storage to cellular damage. Biochim Biophys Acta. 2009, 1793: 684-696. 10.1016/j.bbamcr.2008.12.001.PubMed Ballabio A, Gieselmann V: Lysosomal disorders: from storage to cellular damage. Biochim Biophys Acta. 2009, 1793: 684-696. 10.1016/j.bbamcr.2008.12.001.PubMed
117.
go back to reference Klein D, Bussow H, Fewou SN, Gieselmann V: Exocytosis of storage material in a lysosomal disorder. Biochem Biophys Res Commun. 2005, 327: 663-667. 10.1016/j.bbrc.2004.12.054.PubMed Klein D, Bussow H, Fewou SN, Gieselmann V: Exocytosis of storage material in a lysosomal disorder. Biochem Biophys Res Commun. 2005, 327: 663-667. 10.1016/j.bbrc.2004.12.054.PubMed
118.
go back to reference Callahan JW, Bagshaw RD, Mahuran DJ: The integral membrane of lysosomes: its proteins and their roles in disease. J Proteomics. 2009, 72: 23-33. 10.1016/j.jprot.2008.11.007.PubMed Callahan JW, Bagshaw RD, Mahuran DJ: The integral membrane of lysosomes: its proteins and their roles in disease. J Proteomics. 2009, 72: 23-33. 10.1016/j.jprot.2008.11.007.PubMed
119.
go back to reference Bagshaw RD, Mahuran DJ, Callahan JW: Lysosomal membrane proteomics and biogenesis of lysosomes. Mol Neurobiol. 2005, 32: 27-41. 10.1385/MN:32:1:027.PubMed Bagshaw RD, Mahuran DJ, Callahan JW: Lysosomal membrane proteomics and biogenesis of lysosomes. Mol Neurobiol. 2005, 32: 27-41. 10.1385/MN:32:1:027.PubMed
120.
go back to reference Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, et al: Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy. 2008, 4: 151-175.PubMedPubMedCentral Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, et al: Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy. 2008, 4: 151-175.PubMedPubMedCentral
121.
go back to reference Park YE, Hayashi YK, Bonne G, Arimura T, Noguchi S, Nonaka I, et al: Autophagic degradation of nuclear components in mammalian cells. Autophagy. 2009, 5: 795-804.PubMed Park YE, Hayashi YK, Bonne G, Arimura T, Noguchi S, Nonaka I, et al: Autophagic degradation of nuclear components in mammalian cells. Autophagy. 2009, 5: 795-804.PubMed
122.
go back to reference Kraft C, Deplazes A, Sohrmann M, Peter M: Mature ribosomes are selectively degraded upon starvation by an autophagy pathway requiring the Ubp3p/Bre5p ubiquitin protease. Nat Cell Biol. 2008, 10: 602-610. 10.1038/ncb1723.PubMed Kraft C, Deplazes A, Sohrmann M, Peter M: Mature ribosomes are selectively degraded upon starvation by an autophagy pathway requiring the Ubp3p/Bre5p ubiquitin protease. Nat Cell Biol. 2008, 10: 602-610. 10.1038/ncb1723.PubMed
123.
go back to reference Tasdemir E, Maiuri MC, Tajeddine N, Vitale I, Criollo A, Vicencio JM, et al: Cell cycle-dependent induction of autophagy, mitophagy and reticulophagy. Cell Cycle. 2007, 6: 2263-2267.PubMed Tasdemir E, Maiuri MC, Tajeddine N, Vitale I, Criollo A, Vicencio JM, et al: Cell cycle-dependent induction of autophagy, mitophagy and reticulophagy. Cell Cycle. 2007, 6: 2263-2267.PubMed
124.
go back to reference Dengjel J, Kristensen AR, Andersen JS: Ordered bulk degradation via autophagy. Autophagy. 2008, 4: 1057-1059.PubMed Dengjel J, Kristensen AR, Andersen JS: Ordered bulk degradation via autophagy. Autophagy. 2008, 4: 1057-1059.PubMed
125.
go back to reference Tolkovsky AM: Mitophagy. Biochem Biophys Acta. 2009, 1793: 1508-1515. 10.1016/j.bbamcr.2009.03.002.PubMed Tolkovsky AM: Mitophagy. Biochem Biophys Acta. 2009, 1793: 1508-1515. 10.1016/j.bbamcr.2009.03.002.PubMed
126.
go back to reference Sakai Y, Oku M, Klei van der IJ, Kiel JA: Pexophagy: autophagic degradation of peroxisomes. Biochem Biophys Acta. 2006, 1763: 1767-1775. 10.1016/j.bbamcr.2006.08.023.PubMed Sakai Y, Oku M, Klei van der IJ, Kiel JA: Pexophagy: autophagic degradation of peroxisomes. Biochem Biophys Acta. 2006, 1763: 1767-1775. 10.1016/j.bbamcr.2006.08.023.PubMed
127.
go back to reference Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D: Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004, 305: 1292-1295. 10.1126/science.1101738.PubMed Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D: Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004, 305: 1292-1295. 10.1126/science.1101738.PubMed
128.
go back to reference Qiao L, Zhang J: Inhibition of lysosomal functions reduces proteasomal activity. Neurosci Lett. 2009, 456: 15-19. 10.1016/j.neulet.2009.03.085.PubMed Qiao L, Zhang J: Inhibition of lysosomal functions reduces proteasomal activity. Neurosci Lett. 2009, 456: 15-19. 10.1016/j.neulet.2009.03.085.PubMed
129.
go back to reference Nijssen PC, Brusse E, Leyten AC, Martin JJ, Teepen JL, Roos RA: Autosomal dominant adult neuronal ceroid lipofuscinosis: parkinsonism due to both striatal and nigral dysfunction. Mov Disord. 2002, 17: 482-487. 10.1002/mds.10104.PubMed Nijssen PC, Brusse E, Leyten AC, Martin JJ, Teepen JL, Roos RA: Autosomal dominant adult neuronal ceroid lipofuscinosis: parkinsonism due to both striatal and nigral dysfunction. Mov Disord. 2002, 17: 482-487. 10.1002/mds.10104.PubMed
130.
go back to reference Zimran A, Neudorfer O, Elstein D: The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med. 2005, 352: 728-731. 10.1056/NEJM200502173520719.PubMed Zimran A, Neudorfer O, Elstein D: The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med. 2005, 352: 728-731. 10.1056/NEJM200502173520719.PubMed
131.
go back to reference Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, Cid LP, et al: Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet. 2006, 38: 1184-1191. 10.1038/ng1884.PubMed Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, Cid LP, et al: Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet. 2006, 38: 1184-1191. 10.1038/ng1884.PubMed
132.
go back to reference Sidransky E, Nalls MA, Aasly JO, haron-Peretz J, Annesi G, Barbosa ER, et al: Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009, 361: 1651-1661. 10.1056/NEJMoa0901281.PubMedPubMedCentral Sidransky E, Nalls MA, Aasly JO, haron-Peretz J, Annesi G, Barbosa ER, et al: Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009, 361: 1651-1661. 10.1056/NEJMoa0901281.PubMedPubMedCentral
133.
go back to reference Goker-Alpan O, Giasson BI, Eblan MJ, Nguyen J, Hurtig HI, Lee VM, et al: Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology. 2006 Goker-Alpan O, Giasson BI, Eblan MJ, Nguyen J, Hurtig HI, Lee VM, et al: Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology. 2006
134.
go back to reference Wong K, Sidransky E, Verma A, Mixon T, Sandberg GD, Wakefield LK, et al: Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab. 2004, 82: 192-207. 10.1016/j.ymgme.2004.04.011.PubMed Wong K, Sidransky E, Verma A, Mixon T, Sandberg GD, Wakefield LK, et al: Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab. 2004, 82: 192-207. 10.1016/j.ymgme.2004.04.011.PubMed
135.
go back to reference Saito Y, Suzuki K, Hulette CM, Murayama S: Aberrant phosphorylation of alpha-synuclein in human Niemann-Pick type C1 disease. J Neuropathol Exp Neurol. 2004, 63: 323-328.PubMed Saito Y, Suzuki K, Hulette CM, Murayama S: Aberrant phosphorylation of alpha-synuclein in human Niemann-Pick type C1 disease. J Neuropathol Exp Neurol. 2004, 63: 323-328.PubMed
136.
go back to reference Suzuki K, Iseki E, Togo T, Yamaguchi A, Katsuse O, Katsuyama K, et al: Neuronal and glial accumulation of alpha- and beta-synucleins in human lipidoses. Acta Neuropathol (Berl). 2007, 114: 481-489. 10.1007/s00401-007-0264-z. Suzuki K, Iseki E, Togo T, Yamaguchi A, Katsuse O, Katsuyama K, et al: Neuronal and glial accumulation of alpha- and beta-synucleins in human lipidoses. Acta Neuropathol (Berl). 2007, 114: 481-489. 10.1007/s00401-007-0264-z.
137.
go back to reference Lavrov AY, Ilyna ES, Zakharova EY, Boukina AM, Tishkanina SV: The first three Russian cases of classical, late-infantile, neuronal ceroid lipofuscinosis. Eur J Paediatr Neurol. 2002, 6: 161-164. 10.1053/ejpn.2002.0584.PubMed Lavrov AY, Ilyna ES, Zakharova EY, Boukina AM, Tishkanina SV: The first three Russian cases of classical, late-infantile, neuronal ceroid lipofuscinosis. Eur J Paediatr Neurol. 2002, 6: 161-164. 10.1053/ejpn.2002.0584.PubMed
138.
go back to reference Siintola E, Partanen S, Stromme P, Haapanen A, Haltia M, Maehlen J, et al: Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis. Brain. 2006, 129: 1438-1445. 10.1093/brain/awl107.PubMed Siintola E, Partanen S, Stromme P, Haapanen A, Haltia M, Maehlen J, et al: Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis. Brain. 2006, 129: 1438-1445. 10.1093/brain/awl107.PubMed
139.
go back to reference Steinfeld R, Reinhardt K, Schreiber K, Hillebrand M, Kraetzner R, Bruck W, et al: Cathepsin D deficiency is associated with a human neurodegenerative disorder. Am J Hum Genet. 2006, 78: 988-998. 10.1086/504159.PubMedPubMedCentral Steinfeld R, Reinhardt K, Schreiber K, Hillebrand M, Kraetzner R, Bruck W, et al: Cathepsin D deficiency is associated with a human neurodegenerative disorder. Am J Hum Genet. 2006, 78: 988-998. 10.1086/504159.PubMedPubMedCentral
140.
go back to reference Cullen V, Lindfors M, Ng J, Paetau A, Swinton E, Kolodziej P, et al: Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. Mol Brain. 2009, 2: 5-10.1186/1756-6606-2-5.PubMedPubMedCentral Cullen V, Lindfors M, Ng J, Paetau A, Swinton E, Kolodziej P, et al: Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. Mol Brain. 2009, 2: 5-10.1186/1756-6606-2-5.PubMedPubMedCentral
141.
go back to reference Luiro K, Kopra O, Blom T, Gentile M, Mitchison HM, Hovatta I, et al: Batten disease (JNCL) is linked to disturbances in mitochondrial, cytoskeletal, and synaptic compartments. J Neurosci Res. 2006, 84: 1124-1138. 10.1002/jnr.21015.PubMed Luiro K, Kopra O, Blom T, Gentile M, Mitchison HM, Hovatta I, et al: Batten disease (JNCL) is linked to disturbances in mitochondrial, cytoskeletal, and synaptic compartments. J Neurosci Res. 2006, 84: 1124-1138. 10.1002/jnr.21015.PubMed
142.
go back to reference Jolly RD, Brown S, Das AM, Walkley SU: Mitochondrial dysfunction in the neuronal ceroid-lipofuscinoses (Batten disease). Neurochem Int. 2002, 40: 565-571. 10.1016/S0197-0186(01)00128-0.PubMed Jolly RD, Brown S, Das AM, Walkley SU: Mitochondrial dysfunction in the neuronal ceroid-lipofuscinoses (Batten disease). Neurochem Int. 2002, 40: 565-571. 10.1016/S0197-0186(01)00128-0.PubMed
143.
go back to reference Anglade P, Vyas S, Javoy-Agid F, Herrero MT, Michel PP, Marquez J, et al: Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol. 1997, 12: 25-31.PubMed Anglade P, Vyas S, Javoy-Agid F, Herrero MT, Michel PP, Marquez J, et al: Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol. 1997, 12: 25-31.PubMed
144.
go back to reference Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, et al: Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol. 2005, 64: 113-122.PubMed Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, et al: Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol. 2005, 64: 113-122.PubMed
145.
go back to reference Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, et al: Macroautophagy--a novel Beta-amyloid peptide-generating pathway activated in Alzheimer's disease. J Cell Biol. 2005, 171: 87-98. 10.1083/jcb.200505082.PubMedPubMedCentral Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, et al: Macroautophagy--a novel Beta-amyloid peptide-generating pathway activated in Alzheimer's disease. J Cell Biol. 2005, 171: 87-98. 10.1083/jcb.200505082.PubMedPubMedCentral
146.
go back to reference Yu WH, Dorado B, Figueroa HY, Wang L, Planel E, Cookson MR, et al: Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein. Am J Pathol. 2009, 175: 736-747. 10.2353/ajpath.2009.080928.PubMedPubMedCentral Yu WH, Dorado B, Figueroa HY, Wang L, Planel E, Cookson MR, et al: Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein. Am J Pathol. 2009, 175: 736-747. 10.2353/ajpath.2009.080928.PubMedPubMedCentral
147.
go back to reference Butler D, Nixon RA, Bahr BA: Potential compensatory responses through autophagic/lysosomal pathways in neurodegenerative diseases. Autophagy. 2006, 2: 234-237.PubMed Butler D, Nixon RA, Bahr BA: Potential compensatory responses through autophagic/lysosomal pathways in neurodegenerative diseases. Autophagy. 2006, 2: 234-237.PubMed
148.
go back to reference Butler D, Brown QB, Chin DJ, Batey L, Karim S, Mutneja MS, et al: Cellular responses to protein accumulation involve autophagy and lysosomal enzyme activation. Rejuvenation Res. 2005, 8: 227-237. 10.1089/rej.2005.8.227.PubMed Butler D, Brown QB, Chin DJ, Batey L, Karim S, Mutneja MS, et al: Cellular responses to protein accumulation involve autophagy and lysosomal enzyme activation. Rejuvenation Res. 2005, 8: 227-237. 10.1089/rej.2005.8.227.PubMed
149.
go back to reference Cataldo AM, Barnett JL, Pieroni C, Nixon RA: Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. J Neurosci. 1997, 17: 6142-6151.PubMed Cataldo AM, Barnett JL, Pieroni C, Nixon RA: Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. J Neurosci. 1997, 17: 6142-6151.PubMed
150.
go back to reference Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH: Alterations in lysosomal and proteasomal markers in Parkinson's disease: Relationship to alpha-synuclein inclusions. Neurobiol Dis. 2009, 35: 385-398. 10.1016/j.nbd.2009.05.023.PubMed Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH: Alterations in lysosomal and proteasomal markers in Parkinson's disease: Relationship to alpha-synuclein inclusions. Neurobiol Dis. 2009, 35: 385-398. 10.1016/j.nbd.2009.05.023.PubMed
151.
go back to reference Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA: Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci. 2001, 21: 9549-9560.PubMed Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA: Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci. 2001, 21: 9549-9560.PubMed
152.
go back to reference Martinez-Vicente M, Talloczy Z, Kaushik S, Massey AC, Mazzulli J, Mosharov EV, et al: Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest. 2008, 118: 777-788.PubMedPubMedCentral Martinez-Vicente M, Talloczy Z, Kaushik S, Massey AC, Mazzulli J, Mosharov EV, et al: Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest. 2008, 118: 777-788.PubMedPubMedCentral
153.
go back to reference Erickson AH, Blobel G: Carboxyl-terminal proteolytic processing during biosynthesis of the lysosomal enzymes beta-glucuronidase and cathepsin D. Biochemistry. 1983, 22: 5201-5205. 10.1021/bi00291a021.PubMed Erickson AH, Blobel G: Carboxyl-terminal proteolytic processing during biosynthesis of the lysosomal enzymes beta-glucuronidase and cathepsin D. Biochemistry. 1983, 22: 5201-5205. 10.1021/bi00291a021.PubMed
154.
go back to reference Zubenko GS, Park FJ, Jones EW: Mutations in PEP4 locus of Saccharomyces cerevisiae block final step in maturation of two vacuolar hydrolases. Proc Natl Acad Sci USA. 1983, 80: 510-514. 10.1073/pnas.80.2.510.PubMedPubMedCentral Zubenko GS, Park FJ, Jones EW: Mutations in PEP4 locus of Saccharomyces cerevisiae block final step in maturation of two vacuolar hydrolases. Proc Natl Acad Sci USA. 1983, 80: 510-514. 10.1073/pnas.80.2.510.PubMedPubMedCentral
155.
go back to reference Woolford CA, Daniels LB, Park FJ, Jones EW, Van Arsdell JN, Innis MA: The PEP4 gene encodes an aspartyl protease implicated in the posttranslational regulation of Saccharomyces cerevisiae vacuolar hydrolases. Mol Cell Biol. 1986, 6: 2500-2510.PubMedPubMedCentral Woolford CA, Daniels LB, Park FJ, Jones EW, Van Arsdell JN, Innis MA: The PEP4 gene encodes an aspartyl protease implicated in the posttranslational regulation of Saccharomyces cerevisiae vacuolar hydrolases. Mol Cell Biol. 1986, 6: 2500-2510.PubMedPubMedCentral
156.
go back to reference Woolford CA, Noble JA, Garman JD, Tam MF, Innis MA, Jones EW: Phenotypic analysis of proteinase A mutants. Implications for autoactivation and the maturation pathway of the vacuolar hydrolases of Saccharomyces cerevisiae. J Biol Chem. 1993, 268: 8990-8998.PubMed Woolford CA, Noble JA, Garman JD, Tam MF, Innis MA, Jones EW: Phenotypic analysis of proteinase A mutants. Implications for autoactivation and the maturation pathway of the vacuolar hydrolases of Saccharomyces cerevisiae. J Biol Chem. 1993, 268: 8990-8998.PubMed
157.
go back to reference Marques M, Mojzita D, Amorim MA, Almeida T, Hohmann S, Moradas-Ferreira P, et al: The Pep4p vacuolar proteinase contributes to the turnover of oxidized proteins but PEP4 overexpression is not sufficient to increase chronological lifespan in Saccharomyces cerevisiae. Microbiology. 2006, 152: 3595-3605. 10.1099/mic.0.29040-0.PubMed Marques M, Mojzita D, Amorim MA, Almeida T, Hohmann S, Moradas-Ferreira P, et al: The Pep4p vacuolar proteinase contributes to the turnover of oxidized proteins but PEP4 overexpression is not sufficient to increase chronological lifespan in Saccharomyces cerevisiae. Microbiology. 2006, 152: 3595-3605. 10.1099/mic.0.29040-0.PubMed
158.
go back to reference Koike M, Shibata M, Waguri S, Yoshimura K, Tanida I, Kominami E, et al: Participation of autophagy in storage of lysosomes in neurons from mouse models of neuronal ceroid-lipofuscinoses (Batten disease). Am J Pathol. 2005, 167: 1713-1728.PubMedPubMedCentral Koike M, Shibata M, Waguri S, Yoshimura K, Tanida I, Kominami E, et al: Participation of autophagy in storage of lysosomes in neurons from mouse models of neuronal ceroid-lipofuscinoses (Batten disease). Am J Pathol. 2005, 167: 1713-1728.PubMedPubMedCentral
159.
go back to reference Koike M, Shibata M, Ohsawa Y, Nakanishi H, Koga T, Kametaka S, et al: Involvement of two different cell death pathways in retinal atrophy of cathepsin D-deficient mice. Mol Cell Neurosci. 2003, 22: 146-161. 10.1016/S1044-7431(03)00035-6.PubMed Koike M, Shibata M, Ohsawa Y, Nakanishi H, Koga T, Kametaka S, et al: Involvement of two different cell death pathways in retinal atrophy of cathepsin D-deficient mice. Mol Cell Neurosci. 2003, 22: 146-161. 10.1016/S1044-7431(03)00035-6.PubMed
160.
go back to reference Nakanishi H, Zhang J, Koike M, Nishioku T, Okamoto Y, Kominami E, et al: Involvement of nitric oxide released from microglia-macrophages in pathological changes of cathepsin D-deficient mice. J Neurosci. 2001, 21: 7526-7533.PubMed Nakanishi H, Zhang J, Koike M, Nishioku T, Okamoto Y, Kominami E, et al: Involvement of nitric oxide released from microglia-macrophages in pathological changes of cathepsin D-deficient mice. J Neurosci. 2001, 21: 7526-7533.PubMed
161.
go back to reference Koike M, Nakanishi H, Saftig P, Ezaki J, Isahara K, Ohsawa Y, et al: Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons. J Neurosci. 2000, 20: 6898-6906.PubMed Koike M, Nakanishi H, Saftig P, Ezaki J, Isahara K, Ohsawa Y, et al: Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons. J Neurosci. 2000, 20: 6898-6906.PubMed
162.
go back to reference Saftig P, Hetman M, Schmahl W, Weber K, Heine L, Mossmann H, et al: Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J. 1995, 14: 3599-3608.PubMedPubMedCentral Saftig P, Hetman M, Schmahl W, Weber K, Heine L, Mossmann H, et al: Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J. 1995, 14: 3599-3608.PubMedPubMedCentral
163.
go back to reference Qiao L, Hamamichi S, Caldwell KA, Caldwell GA, Yacoubian TA, Wilson S, et al: Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol Brain. 2008, 1: 17-10.1186/1756-6606-1-17.PubMedPubMedCentral Qiao L, Hamamichi S, Caldwell KA, Caldwell GA, Yacoubian TA, Wilson S, et al: Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol Brain. 2008, 1: 17-10.1186/1756-6606-1-17.PubMedPubMedCentral
164.
go back to reference Hasegawa M, Fujiwara H, Nonaka T, Wakabayashi K, Takahashi H, Lee VM, et al: Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J Biol Chem. 2002, 277: 49071-49076. 10.1074/jbc.M208046200.PubMed Hasegawa M, Fujiwara H, Nonaka T, Wakabayashi K, Takahashi H, Lee VM, et al: Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J Biol Chem. 2002, 277: 49071-49076. 10.1074/jbc.M208046200.PubMed
165.
go back to reference Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, et al: alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002, 4: 160-164. 10.1038/ncb841.PubMed Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, et al: alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002, 4: 160-164. 10.1038/ncb841.PubMed
166.
go back to reference Yang Q, She H, Gearing M, Colla E, Lee M, Shacka JJ, et al: Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy. Science. 2009, 323: 124-127. 10.1126/science.1166088.PubMedPubMedCentral Yang Q, She H, Gearing M, Colla E, Lee M, Shacka JJ, et al: Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy. Science. 2009, 323: 124-127. 10.1126/science.1166088.PubMedPubMedCentral
167.
go back to reference Tang CH, Lee JW, Galvez MG, Robillard L, Mole SE, Chapman HA: Murine cathepsin F deficiency causes neuronal lipofuscinosis and late-onset neurological disease. Mol Cell Biol. 2006, 26: 2309-2316. 10.1128/MCB.26.6.2309-2316.2006.PubMedPubMedCentral Tang CH, Lee JW, Galvez MG, Robillard L, Mole SE, Chapman HA: Murine cathepsin F deficiency causes neuronal lipofuscinosis and late-onset neurological disease. Mol Cell Biol. 2006, 26: 2309-2316. 10.1128/MCB.26.6.2309-2316.2006.PubMedPubMedCentral
168.
go back to reference Yamamoto A, Cremona ML, Rothman JE: Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway. J Cell Biol. 2006, 172: 719-731. 10.1083/jcb.200510065.PubMedPubMedCentral Yamamoto A, Cremona ML, Rothman JE: Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway. J Cell Biol. 2006, 172: 719-731. 10.1083/jcb.200510065.PubMedPubMedCentral
169.
go back to reference Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC: Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem. 2007, 282: 5641-5652. 10.1074/jbc.M609532200.PubMed Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC: Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem. 2007, 282: 5641-5652. 10.1074/jbc.M609532200.PubMed
170.
go back to reference Berger Z, Ravikumar B, Menzies FM, Oroz LG, Underwood BR, Pangalos MN, et al: Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet. 2006, 15: 433-442. 10.1093/hmg/ddi458.PubMed Berger Z, Ravikumar B, Menzies FM, Oroz LG, Underwood BR, Pangalos MN, et al: Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet. 2006, 15: 433-442. 10.1093/hmg/ddi458.PubMed
171.
go back to reference Sarkar S, Floto RA, Berger Z, Imarisio S, Cordenier A, Pasco M, et al: Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol. 2005, 170: 1101-1111. 10.1083/jcb.200504035.PubMedPubMedCentral Sarkar S, Floto RA, Berger Z, Imarisio S, Cordenier A, Pasco M, et al: Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol. 2005, 170: 1101-1111. 10.1083/jcb.200504035.PubMedPubMedCentral
172.
go back to reference Sarkar S, Rubinsztein DC: Inositol and IP3 Levels Regulate Autophagy: Biology and Therapeutic Speculations. Autophagy. 2006, 2: 132-134.PubMed Sarkar S, Rubinsztein DC: Inositol and IP3 Levels Regulate Autophagy: Biology and Therapeutic Speculations. Autophagy. 2006, 2: 132-134.PubMed
173.
go back to reference Menzies FM, Ravikumar B, Rubinsztein DC: Protective roles for induction of autophagy in multiple proteinopathies. Autophagy. 2006, 2: 224-225.PubMed Menzies FM, Ravikumar B, Rubinsztein DC: Protective roles for induction of autophagy in multiple proteinopathies. Autophagy. 2006, 2: 224-225.PubMed
174.
go back to reference Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, et al: Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet. 2004, 36: 585-595. 10.1038/ng1362.PubMed Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, et al: Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet. 2004, 36: 585-595. 10.1038/ng1362.PubMed
175.
go back to reference Sarkar S, Krishna G, Imarisio S, Saiki S, O'Kane CJ, Rubinsztein DC: A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum Mol Genet. 2008, 17: 170-178. 10.1093/hmg/ddm294.PubMed Sarkar S, Krishna G, Imarisio S, Saiki S, O'Kane CJ, Rubinsztein DC: A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum Mol Genet. 2008, 17: 170-178. 10.1093/hmg/ddm294.PubMed
176.
go back to reference Hossain S, Alim A, Takeda K, Kaji H, Shinoda T, Ueda K: Limited proteolysis of NACP/alpha-synuclein. J Alzheimers Dis. 2001, 3: 577-584.PubMed Hossain S, Alim A, Takeda K, Kaji H, Shinoda T, Ueda K: Limited proteolysis of NACP/alpha-synuclein. J Alzheimers Dis. 2001, 3: 577-584.PubMed
177.
go back to reference Hodara R, Norris EH, Giasson BI, Mishizen-Eberz AJ, Lynch DR, Lee VM, et al: Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J Biol Chem. 2004, 279: 47746-47753. 10.1074/jbc.M408906200.PubMed Hodara R, Norris EH, Giasson BI, Mishizen-Eberz AJ, Lynch DR, Lee VM, et al: Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J Biol Chem. 2004, 279: 47746-47753. 10.1074/jbc.M408906200.PubMed
178.
go back to reference Sevlever D, Jiang P, Yen SH: Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Biochemistry. 2008, 47: 9678-9687. 10.1021/bi800699v.PubMedPubMedCentral Sevlever D, Jiang P, Yen SH: Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Biochemistry. 2008, 47: 9678-9687. 10.1021/bi800699v.PubMedPubMedCentral
179.
go back to reference Takahashi T, Yamashita H, Nakamura T, Nagano Y, Nakamura S: Tyrosine 125 of alpha-synuclein plays a critical role for dimerization following nitrative stress. Brain Res. 2002, 938: 73-80. 10.1016/S0006-8993(02)02498-8.PubMed Takahashi T, Yamashita H, Nakamura T, Nagano Y, Nakamura S: Tyrosine 125 of alpha-synuclein plays a critical role for dimerization following nitrative stress. Brain Res. 2002, 938: 73-80. 10.1016/S0006-8993(02)02498-8.PubMed
180.
go back to reference Duda JE, Giasson BI, Chen Q, Gur TL, Hurtig HI, Stern MB, et al: Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am J Pathol. 2000, 157: 1439-1445.PubMedPubMedCentral Duda JE, Giasson BI, Chen Q, Gur TL, Hurtig HI, Stern MB, et al: Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am J Pathol. 2000, 157: 1439-1445.PubMedPubMedCentral
181.
go back to reference Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, et al: Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science. 2000, 290: 985-989. 10.1126/science.290.5493.985.PubMed Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, et al: Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science. 2000, 290: 985-989. 10.1126/science.290.5493.985.PubMed
182.
go back to reference McLean PJ, Kawamata H, Hyman BT: Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience. 2001, 104: 901-912. 10.1016/S0306-4522(01)00113-0.PubMed McLean PJ, Kawamata H, Hyman BT: Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience. 2001, 104: 901-912. 10.1016/S0306-4522(01)00113-0.PubMed
183.
go back to reference Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, et al: Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science. 2006, 313: 324-328. 10.1126/science.1129462.PubMedPubMedCentral Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, et al: Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science. 2006, 313: 324-328. 10.1126/science.1129462.PubMedPubMedCentral
184.
go back to reference St Martin JL, Klucken J, Outeiro TF, Nguyen P, Keller-McGandy C, Cantuti-Castelvetri I, et al: Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J Neurochem. 2007, 100: 1449-1457.PubMed St Martin JL, Klucken J, Outeiro TF, Nguyen P, Keller-McGandy C, Cantuti-Castelvetri I, et al: Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J Neurochem. 2007, 100: 1449-1457.PubMed
185.
go back to reference Gitler AD, Chesi A, Geddie ML, Strathearn KE, Hamamichi S, Hill KJ, et al: Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet. 2009, 41: 308-315. 10.1038/ng.300.PubMedPubMedCentral Gitler AD, Chesi A, Geddie ML, Strathearn KE, Hamamichi S, Hill KJ, et al: Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet. 2009, 41: 308-315. 10.1038/ng.300.PubMedPubMedCentral
Metadata
Title
Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease
Authors
Lonnie Schneider
Jianhua Zhang
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Neurodegeneration / Issue 1/2010
Electronic ISSN: 1750-1326
DOI
https://doi.org/10.1186/1750-1326-5-14

Other articles of this Issue 1/2010

Molecular Neurodegeneration 1/2010 Go to the issue